Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Aaron S. Kelly, Richard M. Bergenstal, J. M. Gonzalez-Campoy, Harold Katz, Alan J. Bank

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs. metformin on endothelial function in patients with obesity and pre-diabetes.Methods: We performed a randomized, open-label, clinical trial in 50 non-diabetic individuals (mean age 58.5 ± 10.0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin. Microvascular endothelial function, assessed by digital reactive hyperemia (reactive hyperemic index: RHI), C-reactive protein (CRP), circulating oxidized LDL (oxLDL), and vascular cell adhesion molecule-1 (VCAM-1) were measured at baseline and 3-months. Seven subjects with IGT participated in a sub-study comparing the effects of pre-administration of exenatide and metformin on postprandial endothelial function.Results: There were no differences for the change in RHI (Δ exenatide: 0.01 ± 0.68 vs. Δ metformin: -0.17 ± 0.72, P = 0.348), CRP, oxLDL, or VCAM-1 between exenatide and metformin treatment. Triglycerides were reduced more with exenatide compared to metformin (Δ exenatide: -25.5 ± 45.7 mg/dL vs. Δ metformin: -2.9 ± 22.8 mg/dL, P = 0.032). In the sub-study, there was no difference in postprandial RHI between exenatide and metformin.Conclusions: Three months of exenatide therapy had similar effects on microvascular endothelial function, markers of inflammation, oxidative stress, and vascular activation, as metformin, in patients with obesity and pre-diabetes.Clinical trials registration: This study is registered on http://www.clinicaltrials.gov/: NCT00546728.

Original languageEnglish (US)
Article number64
JournalCardiovascular Diabetology
Volume11
DOIs
StatePublished - Jun 8 2012

Fingerprint

Metformin
Glucose Intolerance
Vascular Cell Adhesion Molecule-1
C-Reactive Protein
Obesity
Clinical Trials
exenatide
Abdominal Obesity
Hyperemia
Blood Vessels
Fasting
Triglycerides
Oxidative Stress
Therapeutics
Inflammation
Glucose

Keywords

  • Endothelial function
  • Exenatide
  • Metformin
  • Obesity
  • Pre-diabetes

Cite this

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes : a randomized trial. / Kelly, Aaron S.; Bergenstal, Richard M.; Gonzalez-Campoy, J. M.; Katz, Harold; Bank, Alan J.

In: Cardiovascular Diabetology, Vol. 11, 64, 08.06.2012.

Research output: Contribution to journalArticle

Kelly, Aaron S. ; Bergenstal, Richard M. ; Gonzalez-Campoy, J. M. ; Katz, Harold ; Bank, Alan J. / Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes : a randomized trial. In: Cardiovascular Diabetology. 2012 ; Vol. 11.
@article{1d62e2984167406fb6ae7f3e6fd8a420,
title = "Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial",
abstract = "Background: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs. metformin on endothelial function in patients with obesity and pre-diabetes.Methods: We performed a randomized, open-label, clinical trial in 50 non-diabetic individuals (mean age 58.5 ± 10.0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin. Microvascular endothelial function, assessed by digital reactive hyperemia (reactive hyperemic index: RHI), C-reactive protein (CRP), circulating oxidized LDL (oxLDL), and vascular cell adhesion molecule-1 (VCAM-1) were measured at baseline and 3-months. Seven subjects with IGT participated in a sub-study comparing the effects of pre-administration of exenatide and metformin on postprandial endothelial function.Results: There were no differences for the change in RHI (Δ exenatide: 0.01 ± 0.68 vs. Δ metformin: -0.17 ± 0.72, P = 0.348), CRP, oxLDL, or VCAM-1 between exenatide and metformin treatment. Triglycerides were reduced more with exenatide compared to metformin (Δ exenatide: -25.5 ± 45.7 mg/dL vs. Δ metformin: -2.9 ± 22.8 mg/dL, P = 0.032). In the sub-study, there was no difference in postprandial RHI between exenatide and metformin.Conclusions: Three months of exenatide therapy had similar effects on microvascular endothelial function, markers of inflammation, oxidative stress, and vascular activation, as metformin, in patients with obesity and pre-diabetes.Clinical trials registration: This study is registered on http://www.clinicaltrials.gov/: NCT00546728.",
keywords = "Endothelial function, Exenatide, Metformin, Obesity, Pre-diabetes",
author = "Kelly, {Aaron S.} and Bergenstal, {Richard M.} and Gonzalez-Campoy, {J. M.} and Harold Katz and Bank, {Alan J.}",
year = "2012",
month = "6",
day = "8",
doi = "10.1186/1475-2840-11-64",
language = "English (US)",
volume = "11",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes

T2 - a randomized trial

AU - Kelly, Aaron S.

AU - Bergenstal, Richard M.

AU - Gonzalez-Campoy, J. M.

AU - Katz, Harold

AU - Bank, Alan J.

PY - 2012/6/8

Y1 - 2012/6/8

N2 - Background: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs. metformin on endothelial function in patients with obesity and pre-diabetes.Methods: We performed a randomized, open-label, clinical trial in 50 non-diabetic individuals (mean age 58.5 ± 10.0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin. Microvascular endothelial function, assessed by digital reactive hyperemia (reactive hyperemic index: RHI), C-reactive protein (CRP), circulating oxidized LDL (oxLDL), and vascular cell adhesion molecule-1 (VCAM-1) were measured at baseline and 3-months. Seven subjects with IGT participated in a sub-study comparing the effects of pre-administration of exenatide and metformin on postprandial endothelial function.Results: There were no differences for the change in RHI (Δ exenatide: 0.01 ± 0.68 vs. Δ metformin: -0.17 ± 0.72, P = 0.348), CRP, oxLDL, or VCAM-1 between exenatide and metformin treatment. Triglycerides were reduced more with exenatide compared to metformin (Δ exenatide: -25.5 ± 45.7 mg/dL vs. Δ metformin: -2.9 ± 22.8 mg/dL, P = 0.032). In the sub-study, there was no difference in postprandial RHI between exenatide and metformin.Conclusions: Three months of exenatide therapy had similar effects on microvascular endothelial function, markers of inflammation, oxidative stress, and vascular activation, as metformin, in patients with obesity and pre-diabetes.Clinical trials registration: This study is registered on http://www.clinicaltrials.gov/: NCT00546728.

AB - Background: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs. metformin on endothelial function in patients with obesity and pre-diabetes.Methods: We performed a randomized, open-label, clinical trial in 50 non-diabetic individuals (mean age 58.5 ± 10.0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin. Microvascular endothelial function, assessed by digital reactive hyperemia (reactive hyperemic index: RHI), C-reactive protein (CRP), circulating oxidized LDL (oxLDL), and vascular cell adhesion molecule-1 (VCAM-1) were measured at baseline and 3-months. Seven subjects with IGT participated in a sub-study comparing the effects of pre-administration of exenatide and metformin on postprandial endothelial function.Results: There were no differences for the change in RHI (Δ exenatide: 0.01 ± 0.68 vs. Δ metformin: -0.17 ± 0.72, P = 0.348), CRP, oxLDL, or VCAM-1 between exenatide and metformin treatment. Triglycerides were reduced more with exenatide compared to metformin (Δ exenatide: -25.5 ± 45.7 mg/dL vs. Δ metformin: -2.9 ± 22.8 mg/dL, P = 0.032). In the sub-study, there was no difference in postprandial RHI between exenatide and metformin.Conclusions: Three months of exenatide therapy had similar effects on microvascular endothelial function, markers of inflammation, oxidative stress, and vascular activation, as metformin, in patients with obesity and pre-diabetes.Clinical trials registration: This study is registered on http://www.clinicaltrials.gov/: NCT00546728.

KW - Endothelial function

KW - Exenatide

KW - Metformin

KW - Obesity

KW - Pre-diabetes

UR - http://www.scopus.com/inward/record.url?scp=84861944029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861944029&partnerID=8YFLogxK

U2 - 10.1186/1475-2840-11-64

DO - 10.1186/1475-2840-11-64

M3 - Article

C2 - 22681705

AN - SCOPUS:84861944029

VL - 11

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

M1 - 64

ER -